BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sivignon A, Bouckaert J, Bernard J, Gouin SG, Barnich N. The potential of FimH as a novel therapeutic target for the treatment of Crohn’s disease. Expert Opinion on Therapeutic Targets 2017;21:837-47. [DOI: 10.1080/14728222.2017.1363184] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
Number Citing Articles
1 Honig G, Larkin PB, Heller C, Hurtado-Lorenzo A. Research-Based Product Innovation to Address Critical Unmet Needs of Patients with Inflammatory Bowel Diseases. Inflamm Bowel Dis 2021;27:S1-S16. [PMID: 34791292 DOI: 10.1093/ibd/izab230] [Reference Citation Analysis]
2 Yau YY, Wasinger VC, Hirten RP, Chuang E, Huntsman M, Stylli J, Shimizu J, Yajnik V, Smith J, Lee SN, Singh S, Wahl C, Leong RW, Sands BE. Current Trends in IBD-Development of Mucosal-Based Biomarkers and a Novel Minimally Invasive Recoverable Sampling System. Inflamm Bowel Dis 2021;27:S17-24. [PMID: 34791290 DOI: 10.1093/ibd/izab179] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Tomasek K, Leithner A, Glatzova I, Lukesch MS, Guet CC, Sixt M. Type 1 piliated uropathogenic Escherichia coli hijack the host immune response by binding to CD14.. [DOI: 10.1101/2021.10.18.464770] [Reference Citation Analysis]
4 Chevalier G, Laveissière A, Desachy G, Barnich N, Sivignon A, Maresca M, Nicoletti C, Di Pasquale E, Martinez-Medina M, Simpson KW, Yajnik V, Sokol H, Plassais J, Strozzi F, Cervino A, Morra R, Bonny C; MOBIDIC Study Investigators. Blockage of bacterial FimH prevents mucosal inflammation associated with Crohn's disease. Microbiome 2021;9:176. [PMID: 34425887 DOI: 10.1186/s40168-021-01135-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
5 Dolle RE, Mcgrane LK, Janetka JW, Hammill JT, Guy RK, Debnath A, Cheuka PM, Manach CL, Chibale K, Elhammer A, Handfield M, Dawson MJ, Donadio S, Park JH, Joslyn A. Anti‐Infective Case Histories. Burger's Medicinal Chemistry and Drug Discovery 2021. [DOI: 10.1002/0471266949.bmc288] [Reference Citation Analysis]
6 Liu J, Ting JP, Al-Azzam S, Ding Y, Afshar S. Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases. Int J Mol Sci 2021;22:2805. [PMID: 33802091 DOI: 10.3390/ijms22062805] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
7 Mousavifar L, Roy R. Recent development in the design of small 'drug-like' and nanoscale glycomimetics against Escherichia coli infections. Drug Discov Today 2021:S1359-6446(21)00110-0. [PMID: 33667654 DOI: 10.1016/j.drudis.2021.02.025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
8 Kurashima Y, Kigoshi T, Murasaki S, Arai F, Shimada K, Seki N, Kim YG, Hase K, Ohno H, Kawano K, Ashida H, Suzuki T, Morimoto M, Saito Y, Sasou A, Goda Y, Yuki Y, Inagaki Y, Iijima H, Suda W, Hattori M, Kiyono H. Pancreatic glycoprotein 2 is a first line of defense for mucosal protection in intestinal inflammation. Nat Commun 2021;12:1067. [PMID: 33594081 DOI: 10.1038/s41467-021-21277-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 15.0] [Reference Citation Analysis]
9 Yang H, Mirsepasi-Lauridsen HC, Struve C, Allaire JM, Sivignon A, Vogl W, Bosman ES, Ma C, Fotovati A, Reid GS, Li X, Petersen AM, Gouin SG, Barnich N, Jacobson K, Yu HB, Krogfelt KA, Vallance BA. Ulcerative Colitis-associated E. coli pathobionts potentiate colitis in susceptible hosts. Gut Microbes 2020;12:1847976. [PMID: 33258388 DOI: 10.1080/19490976.2020.1847976] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
10 Bonfiglio G, Neroni B, Radocchia G, Pompilio A, Mura F, Trancassini M, Di Bonaventura G, Pantanella F, Schippa S. Growth Control of Adherent-Invasive Escherichia coli (AIEC) by the Predator Bacteria Bdellovibrio bacteriovorus: A New Therapeutic Approach for Crohn's Disease Patients. Microorganisms 2019;8:E17. [PMID: 31861852 DOI: 10.3390/microorganisms8010017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
11 Zhang CX, Wang HY, Chen TX. Interactions between Intestinal Microflora/Probiotics and the Immune System. Biomed Res Int 2019;2019:6764919. [PMID: 31828119 DOI: 10.1155/2019/6764919] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 8.7] [Reference Citation Analysis]
12 Psonis JJ, Thanassi DG. Therapeutic Approaches Targeting the Assembly and Function of Chaperone-Usher Pili. Protein Secretion in Bacteria 2019. [DOI: 10.1128/9781683670285.ch13] [Reference Citation Analysis]
13 Mishima Y, Sartor RB. Manipulating resident microbiota to enhance regulatory immune function to treat inflammatory bowel diseases. J Gastroenterol 2020;55:4-14. [PMID: 31482438 DOI: 10.1007/s00535-019-01618-1] [Cited by in Crossref: 45] [Cited by in F6Publishing: 36] [Article Influence: 15.0] [Reference Citation Analysis]
14 Currie KS, Patel L, Sedillo KF. Small-molecule agents for the treatment of inflammatory bowel disease. Bioorganic & Medicinal Chemistry Letters 2019;29:2034-41. [DOI: 10.1016/j.bmcl.2019.06.042] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
15 Psonis JJ, Thanassi DG. Therapeutic Approaches Targeting the Assembly and Function of Chaperone-Usher Pili. EcoSal Plus 2019;8. [PMID: 30873935 DOI: 10.1128/ecosalplus.ESP-0033-2018] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
16 Chung S. Oral and Human Microbiome Research. J Dent Hyg Sci 2019;19:77-85. [DOI: 10.17135/jdhs.2019.19.2.77] [Reference Citation Analysis]
17 Hevey R. Strategies for the Development of Glycomimetic Drug Candidates. Pharmaceuticals (Basel) 2019;12:E55. [PMID: 30978966 DOI: 10.3390/ph12020055] [Cited by in Crossref: 55] [Cited by in F6Publishing: 54] [Article Influence: 18.3] [Reference Citation Analysis]
18 Mousavifar L, Touaibia M, Roy R. Development of Mannopyranoside Therapeutics against Adherent-Invasive Escherichia coli Infections. Acc Chem Res 2018;51:2937-48. [PMID: 30289687 DOI: 10.1021/acs.accounts.8b00397] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
19 Dumych T, Bridot C, Gouin SG, Lensink MF, Paryzhak S, Szunerits S, Blossey R, Bilyy R, Bouckaert J, Krammer EM. A Novel Integrated Way for Deciphering the Glycan Code for the FimH Lectin. Molecules 2018;23:E2794. [PMID: 30373288 DOI: 10.3390/molecules23112794] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
20 Kalograiaki I, Abellán-flos M, Fernández LÁ, Menéndez M, Vincent SP, Solís D. Direct Evaluation of Live Uropathogenic Escherichia coli Adhesion and Efficiency of Antiadhesive Compounds Using a Simple Microarray Approach. Anal Chem 2018;90:12314-21. [DOI: 10.1021/acs.analchem.8b04235] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
21 Krammer EM, de Ruyck J, Roos G, Bouckaert J, Lensink MF. Targeting Dynamical Binding Processes in the Design of Non-Antibiotic Anti-Adhesives by Molecular Simulation-The Example of FimH. Molecules 2018;23:E1641. [PMID: 29976867 DOI: 10.3390/molecules23071641] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
22 Ebrahim-Saraie HS, Nezhad NZ, Heidari H, Motamedifar A, Motamedifar M. Detection of Antimicrobial Susceptibility and Integrons Among Extended-spectrum β-lactamase Producing Uropathogenic Escherichia coli Isolates in Southwestern Iran. Oman Med J 2018;33:218-23. [PMID: 29896329 DOI: 10.5001/omj.2018.40] [Cited by in Crossref: 13] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
23 González A, Fillat MF, Lanas Á. Transcriptional regulators: valuable targets for novel antibacterial strategies. Future Med Chem 2018;10:541-60. [PMID: 29461098 DOI: 10.4155/fmc-2017-0181] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]